BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs
21 déc. 2023 08h00 HE
|
BioNTech SE
Breakthrough-Therapy-Status basiert auf Phase-1/2-Daten zur Sicherheit und Wirksamkeit in Patientinnen mit Human Epidermal Growth Factor Receptor 2 („HER2“) -exprimierendem, fortgeschrittenen...
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
21 déc. 2023 08h00 HE
|
BioNTech SE
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of...
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
12 déc. 2023 05h15 HE
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
07 déc. 2023 19h51 HE
|
EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung
29 nov. 2023 08h30 HE
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 antigen was discovered using OBT’s proprietary OGAP® drug discovery...
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
26 nov. 2023 23h37 HE
|
EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
20 nov. 2023 10h00 HE
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
Data Converter Market Size worth $8.28 Billion, Globally, by 2028 - Exclusive Report by The Insight Partners
10 nov. 2023 11h45 HE
|
The Insight Partners
Pune, India., Nov. 10, 2023 (GLOBE NEWSWIRE) -- According to a new report published by The Insight Partners on “Data Converter Market Size and Forecast (2022–2028), Global and Regional Share,...
November is Pancreatic Cancer Awareness Month
08 nov. 2023 04h00 HE
|
EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
06 nov. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...